FI66604C - Foerfarande foer framstaellning av nya 5h-2,3-bensodiazepinderivat med inverkan pao det centrala nervsystemet - Google Patents
Foerfarande foer framstaellning av nya 5h-2,3-bensodiazepinderivat med inverkan pao det centrala nervsystemet Download PDFInfo
- Publication number
- FI66604C FI66604C FI793209A FI793209A FI66604C FI 66604 C FI66604 C FI 66604C FI 793209 A FI793209 A FI 793209A FI 793209 A FI793209 A FI 793209A FI 66604 C FI66604 C FI 66604C
- Authority
- FI
- Finland
- Prior art keywords
- benzodiazepine
- methyl
- general formula
- group
- ethyl
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 19
- -1 hydroxy - Chemical class 0.000 claims description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 15
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 13
- YVOHCRLDUPTKOH-UHFFFAOYSA-N 5h-2,3-benzodiazepine Chemical class C1C=NN=CC2=CC=CC=C12 YVOHCRLDUPTKOH-UHFFFAOYSA-N 0.000 claims description 13
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 13
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000007942 carboxylates Chemical class 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- UUDYWELSMJWOIM-UHFFFAOYSA-N isochromen-6-one Chemical compound O1C=CC2=CC(=O)C=CC2=C1 UUDYWELSMJWOIM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 101150090155 R gene Proteins 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 238000006114 decarboxylation reaction Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 239000012429 reaction media Substances 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 229940071182 stannate Drugs 0.000 claims 1
- 125000005402 stannate group Chemical group 0.000 claims 1
- 108700026215 vpr Genes Proteins 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 89
- 229960004592 isopropanol Drugs 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 238000001953 recrystallisation Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 18
- 239000007858 starting material Substances 0.000 description 17
- 239000000155 melt Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical class [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- 229960002501 tofisopam Drugs 0.000 description 4
- OBLULRQNQYXFMR-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-4,7,8-trimethyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(C)=C(C)C=C2C=1C1=CC=C(OC)C(OC)=C1 OBLULRQNQYXFMR-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- QIMSZSRNPDUPBF-UHFFFAOYSA-N 1-(2-fluorophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound FC1=C(C=CC=C1)C1=NN=C(CC2=C1C=C(C(=C2)OC)OC)C QIMSZSRNPDUPBF-UHFFFAOYSA-N 0.000 description 2
- GBOHYJOUGVPNSU-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine-4-carbaldehyde Chemical compound N=1N=C(C=O)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 GBOHYJOUGVPNSU-UHFFFAOYSA-N 0.000 description 2
- DFPIIEOUMLCAGE-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-ol Chemical compound N=1N=C(C)C(CC)C2=CC(O)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 DFPIIEOUMLCAGE-UHFFFAOYSA-N 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- MWBAHRRFJNAKHK-UHFFFAOYSA-N 5-ethyl-1-(3-hydroxy-4-methoxyphenyl)-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-ol Chemical compound N=1N=C(C)C(CC)C2=CC(O)=C(OC)C=C2C=1C1=CC=C(OC)C(O)=C1 MWBAHRRFJNAKHK-UHFFFAOYSA-N 0.000 description 2
- HXKGMQQAXQUEDH-UHFFFAOYSA-N 5-ethyl-7,8-dimethoxy-4-methyl-1-phenyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 HXKGMQQAXQUEDH-UHFFFAOYSA-N 0.000 description 2
- PBCGGWZWRWGTFK-UHFFFAOYSA-N 5h-2,3-benzodiazepine-4-carboxylic acid Chemical class C1C(C(=O)O)=NN=CC2=CC=CC=C21 PBCGGWZWRWGTFK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- JYZRWNFTNZZSKI-UHFFFAOYSA-N CC1=C(OC(=CC2=CC=CC=C2)C3=CC(=C(C=C13)OC)OC)C Chemical compound CC1=C(OC(=CC2=CC=CC=C2)C3=CC(=C(C=C13)OC)OC)C JYZRWNFTNZZSKI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- VQYLGVVODFDFNK-UHFFFAOYSA-N girisopam Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CC(Cl)=C1 VQYLGVVODFDFNK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SQMCFUSVGSBKFK-UHFFFAOYSA-M sodium;5-(cyclohexen-1-yl)-1,5-dimethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1N(C)C(=O)[N-]C(=O)C1(C)C1=CCCCC1 SQMCFUSVGSBKFK-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- KZOARBQGIQVJDQ-UHFFFAOYSA-N 1-(2-benzoyl-4,5-dimethoxyphenyl)propan-2-one Chemical compound C1=C(OC)C(OC)=CC(CC(C)=O)=C1C(=O)C1=CC=CC=C1 KZOARBQGIQVJDQ-UHFFFAOYSA-N 0.000 description 1
- ICOPGIDBZGAWLQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-5H-2,3-benzodiazepine-7,8-diol Chemical compound ClC1=C(C=CC=C1)C1=NN=C(CC2=C1C=C(C(=C2)O)O)C ICOPGIDBZGAWLQ-UHFFFAOYSA-N 0.000 description 1
- NUYJXPGEZFOLHN-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1Cl NUYJXPGEZFOLHN-UHFFFAOYSA-N 0.000 description 1
- HLWPRKYYGMQUDR-UHFFFAOYSA-N 1-(2-chlorophenyl)-7,8-diethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OCC)C(OCC)=CC=2CC(C)=NN=C1C1=CC=CC=C1Cl HLWPRKYYGMQUDR-UHFFFAOYSA-N 0.000 description 1
- BSDRAQVJZCAZRN-UHFFFAOYSA-N 1-(2-chlorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CC=C1Cl BSDRAQVJZCAZRN-UHFFFAOYSA-N 0.000 description 1
- GHQPUNHBHNDUPF-UHFFFAOYSA-N 1-(2-chlorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine;hydrochloride Chemical compound Cl.C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CC=C1Cl GHQPUNHBHNDUPF-UHFFFAOYSA-N 0.000 description 1
- SSBBJNRRCIGTKT-UHFFFAOYSA-N 1-(2-iodophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound IC1=C(C=CC=C1)C1=NN=C(CC2=C1C=C(C(=C2)OC)OC)C SSBBJNRRCIGTKT-UHFFFAOYSA-N 0.000 description 1
- PXCRHBKDVLDPNR-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-4-ethyl-7,8-dimethoxy-5-methyl-5h-2,3-benzodiazepine Chemical compound C12=CC(OC)=C(OC)C=C2C(C)C(CC)=NN=C1C1=CC=C(OC)C(OC)=C1 PXCRHBKDVLDPNR-UHFFFAOYSA-N 0.000 description 1
- SNLLFFAPVUTMFJ-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-4-ethyl-7-methoxy-3-methylisochromen-6-one Chemical compound C=12C=C(OC)C(=O)C=C2C(CC)=C(C)OC=1C1=CC=C(OC)C(OC)=C1 SNLLFFAPVUTMFJ-UHFFFAOYSA-N 0.000 description 1
- OJBNVYQFNDIKEW-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-8-propan-2-yl-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OC)C1=NN=C(C(C2=C1C=C(C=C2)C(C)C)CC)C OJBNVYQFNDIKEW-UHFFFAOYSA-N 0.000 description 1
- XFYJTSJKEJXPAH-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-propyl-5h-2,3-benzodiazepine Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)C(CCC)=NN=C1C1=CC=C(OC)C(OC)=C1 XFYJTSJKEJXPAH-UHFFFAOYSA-N 0.000 description 1
- VUULZNYCOILCIO-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)C=NN=C1C1=CC=C(OC)C(OC)=C1 VUULZNYCOILCIO-UHFFFAOYSA-N 0.000 description 1
- AFNXIFIFZDQRMT-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine-4-carboxylic acid Chemical compound N=1N=C(C(O)=O)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 AFNXIFIFZDQRMT-UHFFFAOYSA-N 0.000 description 1
- VCQFUVLZFBNFJG-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-7-propan-2-yloxy-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC(C)C)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 VCQFUVLZFBNFJG-UHFFFAOYSA-N 0.000 description 1
- WPRPCLBGSNSPRO-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-7-propoxy-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OCCC)=CC=2C(CC)C(C)=NN=C1C1=CC=C(OC)C(OC)=C1 WPRPCLBGSNSPRO-UHFFFAOYSA-N 0.000 description 1
- WYDFDZHLWJDEQZ-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4,5-dimethyl-5h-2,3-benzodiazepine Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN=C(C)C(C)C2=CC(OC)=C(OC)C=C12 WYDFDZHLWJDEQZ-UHFFFAOYSA-N 0.000 description 1
- YNFUOHOMZKWXLU-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN=C(C)CC2=CC(OC)=C(OC)C=C12 YNFUOHOMZKWXLU-UHFFFAOYSA-N 0.000 description 1
- JCMFGVRRVKRCCA-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-7-ethoxy-5-ethyl-8-methoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OCC)=CC=2C(CC)C(C)=NN=C1C1=CC=C(OC)C(OC)=C1 JCMFGVRRVKRCCA-UHFFFAOYSA-N 0.000 description 1
- MGIYLKQMTBPOQV-UHFFFAOYSA-N 1-(3-chlorophenyl)-7,8-diethoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound ClC=1C=C(C=CC=1)C1=NN=C(CC2=C1C=C(C(=C2)OCC)OCC)C MGIYLKQMTBPOQV-UHFFFAOYSA-N 0.000 description 1
- KUKSEFMVEWVLNG-UHFFFAOYSA-N 1-(3-chlorophenyl)-7,8-dimethoxy-4,5-dimethyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C)C(C)=NN=C1C1=CC=CC(Cl)=C1 KUKSEFMVEWVLNG-UHFFFAOYSA-N 0.000 description 1
- NLWAZOPOYVPSLG-UHFFFAOYSA-N 1-(3-fluorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CC(F)=C1 NLWAZOPOYVPSLG-UHFFFAOYSA-N 0.000 description 1
- MZBWWSXMABECGT-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound ClC1=CC=C(C=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C MZBWWSXMABECGT-UHFFFAOYSA-N 0.000 description 1
- GFOIVMZCHFWCER-UHFFFAOYSA-N 1-(4-chlorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=C(Cl)C=C1 GFOIVMZCHFWCER-UHFFFAOYSA-N 0.000 description 1
- VMRDCIDRWYETRF-UHFFFAOYSA-N 1-(furan-2-yl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CO1 VMRDCIDRWYETRF-UHFFFAOYSA-N 0.000 description 1
- QUXODVYZILQUAR-UHFFFAOYSA-N 1-[2-(2-chlorobenzoyl)-4,5-dimethoxyphenyl]propan-2-one Chemical compound C1=C(OC)C(OC)=CC(CC(C)=O)=C1C(=O)C1=CC=CC=C1Cl QUXODVYZILQUAR-UHFFFAOYSA-N 0.000 description 1
- ZXWJNKQFCWPSHS-UHFFFAOYSA-N 1-[2-(2-fluorobenzoyl)-4,5-dimethoxyphenyl]propan-2-one Chemical compound C(C(=O)C)C1=C(C(=O)C2=C(C=CC=C2)F)C=C(C(=C1)OC)OC ZXWJNKQFCWPSHS-UHFFFAOYSA-N 0.000 description 1
- HTTFZIADBLPSGL-UHFFFAOYSA-N 1-[2-(2-iodobenzoyl)-4,5-dimethoxyphenyl]propan-2-one Chemical compound C(C(=O)C)C1=C(C(=O)C2=C(C=CC=C2)I)C=C(C(=C1)OC)OC HTTFZIADBLPSGL-UHFFFAOYSA-N 0.000 description 1
- XCDDYHYPCCEVGO-UHFFFAOYSA-N 1-[2-(3,4-dimethoxybenzoyl)-4,5-dimethoxyphenyl]propan-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C1=CC(OC)=C(OC)C=C1CC(C)=O XCDDYHYPCCEVGO-UHFFFAOYSA-N 0.000 description 1
- HWTOHQPZORLNLF-UHFFFAOYSA-N 1-benzyl-7,8-dimethoxy-4,5-dimethyl-5H-2,3-benzodiazepine Chemical compound C(C1=CC=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)C)C HWTOHQPZORLNLF-UHFFFAOYSA-N 0.000 description 1
- HOMYHMUFNFFNCJ-UHFFFAOYSA-N 1-phenyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical class N=1NC(=O)CC2=CC=CC=C2C=1C1=CC=CC=C1 HOMYHMUFNFFNCJ-UHFFFAOYSA-N 0.000 description 1
- NIBFJPXGNVPNHK-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-4-carbaldehyde Chemical group C1=CC(C=O)=C2OC(F)(F)OC2=C1 NIBFJPXGNVPNHK-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- QZZVNZDYDNOZQK-UHFFFAOYSA-N 2-[[1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-yl]oxy]-N,N-diethylethanamine Chemical compound N=1N=C(C)C(CC)C2=CC(OCCN(CC)CC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 QZZVNZDYDNOZQK-UHFFFAOYSA-N 0.000 description 1
- DOJMUJJXAKFADM-UHFFFAOYSA-N 3-[2-(2-chlorobenzoyl)-4,5-dimethoxyphenyl]pentan-2-one Chemical compound CCC(C(C)=O)C1=CC(OC)=C(OC)C=C1C(=O)C1=CC=CC=C1Cl DOJMUJJXAKFADM-UHFFFAOYSA-N 0.000 description 1
- GFRUAWOAHOQRHA-UHFFFAOYSA-N 3-[2-(2-iodobenzoyl)-4,5-dimethoxyphenyl]pentan-2-one Chemical compound C(C)C(C(=O)C)C1=C(C(=O)C2=C(C=CC=C2)I)C=C(C(=C1)OC)OC GFRUAWOAHOQRHA-UHFFFAOYSA-N 0.000 description 1
- RGAIACSTGBXCMU-UHFFFAOYSA-N 3-[2-(4-chlorobenzoyl)-4,5-dimethoxyphenyl]pentan-2-one Chemical compound C(C)C(C(=O)C)C1=C(C(=O)C2=CC=C(C=C2)Cl)C=C(C(=C1)OC)OC RGAIACSTGBXCMU-UHFFFAOYSA-N 0.000 description 1
- DNPXUUZTDQMFEX-UHFFFAOYSA-N 3-[4,5-dimethoxy-2-(3,4,5-trimethoxybenzoyl)phenyl]pentan-2-one Chemical compound CCC(C(C)=O)C1=CC(OC)=C(OC)C=C1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNPXUUZTDQMFEX-UHFFFAOYSA-N 0.000 description 1
- WCDNMLKUZAGTSF-UHFFFAOYSA-N 3-[[1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5h-2,3-benzodiazepin-7-yl]oxy]-n,n-dimethylpropan-1-amine Chemical compound N=1N=C(C)C(CC)C2=CC(OCCCN(C)C)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 WCDNMLKUZAGTSF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OQTUSGBCCKOANW-UHFFFAOYSA-N 4-(5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)-2-methoxyphenol Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(O)C(OC)=C1 OQTUSGBCCKOANW-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- YQHRIORZKUWFPX-UHFFFAOYSA-N 4-methyl-5h-2,3-benzodiazepine Chemical class C1C(C)=NN=CC2=CC=CC=C21 YQHRIORZKUWFPX-UHFFFAOYSA-N 0.000 description 1
- GNBQJGIRKYHNIO-UHFFFAOYSA-N 5-butyl-1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine;hydrate Chemical compound O.N=1N=C(C)C(CCCC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 GNBQJGIRKYHNIO-UHFFFAOYSA-N 0.000 description 1
- WXNFGGMDTHCBKJ-UHFFFAOYSA-N 5-ethyl-1-(2-fluorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1F WXNFGGMDTHCBKJ-UHFFFAOYSA-N 0.000 description 1
- IGJICDXNJPXILW-UHFFFAOYSA-N 5-ethyl-1-(2-iodophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound IC1=C(C=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C IGJICDXNJPXILW-UHFFFAOYSA-N 0.000 description 1
- SJMLFTGWYGYVGJ-UHFFFAOYSA-N 5-ethyl-1-(3-fluorophenyl)-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC(F)=C1 SJMLFTGWYGYVGJ-UHFFFAOYSA-N 0.000 description 1
- OKJYOBGZHDJJJA-UHFFFAOYSA-N 5-ethyl-1-(3-hydroxy-4-methoxyphenyl)-7-methoxy-4-methyl-5h-2,3-benzodiazepin-8-ol Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(O)C=C2C=1C1=CC=C(OC)C(O)=C1 OKJYOBGZHDJJJA-UHFFFAOYSA-N 0.000 description 1
- XJHIQURRMXPARZ-UHFFFAOYSA-N 5-ethyl-1-(4-hydroxy-3-methoxyphenyl)-4-methyl-5H-2,3-benzodiazepine-7,8-diol Chemical compound COC=1C=C(C=CC=1O)C1=NN=C(C(C2=C1C=C(C(=C2)O)O)CC)C XJHIQURRMXPARZ-UHFFFAOYSA-N 0.000 description 1
- MVJUBSLMLVQYTD-UHFFFAOYSA-N 5-ethyl-1-(4-hydroxy-3-methoxyphenyl)-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-ol Chemical compound N=1N=C(C)C(CC)C2=CC(O)=C(OC)C=C2C=1C1=CC=C(O)C(OC)=C1 MVJUBSLMLVQYTD-UHFFFAOYSA-N 0.000 description 1
- RCTGNTKOLFSJSH-UHFFFAOYSA-N 5-ethyl-7,8-dimethoxy-1-(4-methoxyphenyl)-4-methyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C=C1 RCTGNTKOLFSJSH-UHFFFAOYSA-N 0.000 description 1
- XPVOTAJEGKXLAR-UHFFFAOYSA-N 5-ethyl-7,8-dimethoxy-4-methyl-1-(3,4,5-trimethoxyphenyl)-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC(OC)=C(OC)C(OC)=C1 XPVOTAJEGKXLAR-UHFFFAOYSA-N 0.000 description 1
- WTUAXBSWMAIQAG-UHFFFAOYSA-N 5-ethyl-7-methoxy-1-(3-methoxy-4-phenylmethoxyphenyl)-4-methyl-8-phenylmethoxy-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OCC1=CC=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OCC1=CC=CC=C1)CC)C WTUAXBSWMAIQAG-UHFFFAOYSA-N 0.000 description 1
- AVVSRLJUMOWCSM-UHFFFAOYSA-N 5-ethyl-7-methoxy-1-(3-methoxy-4-propoxyphenyl)-4-methyl-8-propoxy-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OCCC)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OCCC)CC)C AVVSRLJUMOWCSM-UHFFFAOYSA-N 0.000 description 1
- PNKVTDGAOWVBQZ-UHFFFAOYSA-N 5-ethyl-7-methoxy-4-methyl-1-phenyl-5h-2,3-benzodiazepine Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=CC=C2C=1C1=CC=CC=C1 PNKVTDGAOWVBQZ-UHFFFAOYSA-N 0.000 description 1
- XVRSHGGEAVHANN-UHFFFAOYSA-N 5h-2,3-benzodiazepin-4-ylmethanol Chemical class C1C(CO)=NN=CC2=CC=CC=C21 XVRSHGGEAVHANN-UHFFFAOYSA-N 0.000 description 1
- VDSCFXDSWATXGA-UHFFFAOYSA-N 7,8-dimethoxy-1-(2-methoxyphenyl)-4-methyl-5h-2,3-benzodiazepine Chemical compound COC1=CC=CC=C1C1=NN=C(C)CC2=CC(OC)=C(OC)C=C12 VDSCFXDSWATXGA-UHFFFAOYSA-N 0.000 description 1
- SZYQATHWZBRBJH-UHFFFAOYSA-N 7,8-dimethoxy-1-(3-methoxyphenyl)-4-methyl-5h-2,3-benzodiazepine Chemical compound COC1=CC=CC(C=2C3=CC(OC)=C(OC)C=C3CC(C)=NN=2)=C1 SZYQATHWZBRBJH-UHFFFAOYSA-N 0.000 description 1
- PIGVHNHIGYIPDS-UHFFFAOYSA-N 7,8-dimethoxy-4-methyl-1-phenyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CC=C1 PIGVHNHIGYIPDS-UHFFFAOYSA-N 0.000 description 1
- SNHOCWVLRJWZQI-UHFFFAOYSA-N 7,8-dimethoxy-4-methyl-1-thiophen-2-yl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(C)=NN=C1C1=CC=CS1 SNHOCWVLRJWZQI-UHFFFAOYSA-N 0.000 description 1
- MOPZJZUAMLLEAA-UHFFFAOYSA-N 7-[(2-chlorophenyl)methoxy]-1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OC)C1=NN=C(C(C2=C1C=C(C(=C2)OCC1=C(C=CC=C1)Cl)OC)CC)C MOPZJZUAMLLEAA-UHFFFAOYSA-N 0.000 description 1
- YCBRZQSYMVYETD-UHFFFAOYSA-N 7-butan-2-yloxy-1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OC(C)CC)=CC=2C(CC)C(C)=NN=C1C1=CC=C(OC)C(OC)=C1 YCBRZQSYMVYETD-UHFFFAOYSA-N 0.000 description 1
- SBVMHJAMNZXZQZ-UHFFFAOYSA-N 7-butoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1=2C=C(OC)C(OCCCC)=CC=2C(CC)C(C)=NN=C1C1=CC=C(OC)C(OC)=C1 SBVMHJAMNZXZQZ-UHFFFAOYSA-N 0.000 description 1
- VMDWDYFZLRCNGV-UHFFFAOYSA-N 8-butoxy-1-(4-butoxy-3-methoxyphenyl)-5-ethyl-7-methoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OCCCC)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OCCCC)CC)C VMDWDYFZLRCNGV-UHFFFAOYSA-N 0.000 description 1
- FWUZZLAUHXLVSB-UHFFFAOYSA-N 8-ethoxy-1-(4-ethoxy-3-methoxyphenyl)-5-ethyl-7-methoxy-4-methyl-5H-2,3-benzodiazepine Chemical compound COC=1C=C(C=CC=1OCC)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OCC)CC)C FWUZZLAUHXLVSB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- XYPAQJRODDJNTE-UHFFFAOYSA-N C(C1=CC=CC=C1)=C1OC(=C(C2=CC(=C(C=C12)OC)OC)CC)C Chemical compound C(C1=CC=CC=C1)=C1OC(=C(C2=CC(=C(C=C12)OC)OC)CC)C XYPAQJRODDJNTE-UHFFFAOYSA-N 0.000 description 1
- JDILCAMHLDHAPZ-UHFFFAOYSA-N C(C1=CC=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C Chemical compound C(C1=CC=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C JDILCAMHLDHAPZ-UHFFFAOYSA-N 0.000 description 1
- QDCMHTYHSKTTGX-UHFFFAOYSA-N C(C1=CC=CC=C1)C1=NN=C(CC2=C1C=C(C(=C2)OC)OC)C Chemical compound C(C1=CC=CC=C1)C1=NN=C(CC2=C1C=C(C(=C2)OC)OC)C QDCMHTYHSKTTGX-UHFFFAOYSA-N 0.000 description 1
- WNELCOUTUAZBSF-UHFFFAOYSA-N CC1=NN=C(C2=CC3=C(C=C2C1)OCO3)C4=CC=CC=C4Cl Chemical compound CC1=NN=C(C2=CC3=C(C=C2C1)OCO3)C4=CC=CC=C4Cl WNELCOUTUAZBSF-UHFFFAOYSA-N 0.000 description 1
- LAMJRZPWBPILCJ-UHFFFAOYSA-N CCC1=C(C=C(C(OC)=C2)OC)C2=C(C2=CC=CS2)NN=C1C Chemical compound CCC1=C(C=C(C(OC)=C2)OC)C2=C(C2=CC=CS2)NN=C1C LAMJRZPWBPILCJ-UHFFFAOYSA-N 0.000 description 1
- USQOVYLRWBOSQC-HNNXBMFYSA-N CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O Chemical compound CCCCCCNC(=O)Oc1cccc(c1)-c1ccc(cc1F)[C@H](C)C(O)=O USQOVYLRWBOSQC-HNNXBMFYSA-N 0.000 description 1
- IRWWZXCKKDDYDG-UHFFFAOYSA-N CCOC1=C(C=C(C(=C1)CC(=O)C)C(=O)C2=CC(=CC=C2)Cl)OCC Chemical compound CCOC1=C(C=C(C(=C1)CC(=O)C)C(=O)C2=CC(=CC=C2)Cl)OCC IRWWZXCKKDDYDG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JLIXVSJMXUCDJQ-UHFFFAOYSA-N Cl.IC1=C(C=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C Chemical compound Cl.IC1=C(C=CC=C1)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC)CC)C JLIXVSJMXUCDJQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- WKDXAMUVOWOHTL-UHFFFAOYSA-N [1-(2-hydrazinylidenepropyl)-3,4-dimethoxycyclohexa-2,4-dien-1-yl]-(2-iodophenyl)methanone Chemical compound N(N)=C(CC1(C(=O)C2=C(C=CC=C2)I)CC=C(C(=C1)OC)OC)C WKDXAMUVOWOHTL-UHFFFAOYSA-N 0.000 description 1
- TVFKRRFVVCGYJO-UHFFFAOYSA-N [1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-yl] acetate Chemical compound COC=1C=C(C=CC=1OC)C1=NN=C(C(C2=C1C=C(C(=C2)OC(C)=O)OC)CC)C TVFKRRFVVCGYJO-UHFFFAOYSA-N 0.000 description 1
- YIFDOMIQPPIPQF-UHFFFAOYSA-N [2-acetyloxy-4-(7-acetyloxy-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)phenyl] acetate Chemical compound C(C)(=O)OC=1C=C(C=CC=1OC(C)=O)C1=NN=C(C(C2=C1C=C(C(=C2)OC(C)=O)OC)CC)C YIFDOMIQPPIPQF-UHFFFAOYSA-N 0.000 description 1
- GIHRUQONWFYGFS-UHFFFAOYSA-N [4-(8-acetyloxy-5-ethyl-7-methoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)-2-methoxyphenyl] acetate Chemical compound COC=1C=C(C=CC=1OC(C)=O)C1=NN=C(C(C2=C1C=C(C(=C2)OC)OC(C)=O)CC)C GIHRUQONWFYGFS-UHFFFAOYSA-N 0.000 description 1
- DRRVUEKOMRMIMC-UHFFFAOYSA-N [5-(7-acetyloxy-5-ethyl-8-methoxy-4-methyl-5h-2,3-benzodiazepin-1-yl)-2-methoxyphenyl] acetate Chemical compound N=1N=C(C)C(CC)C2=CC(OC(C)=O)=C(OC)C=C2C=1C1=CC=C(OC)C(OC(C)=O)=C1 DRRVUEKOMRMIMC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical group [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- BJYYAMSOIWQPBN-UHFFFAOYSA-N ethyl 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine-4-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)C(C(=O)OCC)=NN=C1C1=CC=C(OC)C(OC)=C1 BJYYAMSOIWQPBN-UHFFFAOYSA-N 0.000 description 1
- AAVAGGUKVWHXPC-UHFFFAOYSA-N ethyl 2-[[1-(3,4-dimethoxyphenyl)-5-ethyl-8-methoxy-4-methyl-5H-2,3-benzodiazepin-7-yl]oxy]acetate Chemical compound COC=1C=C(C=CC1OC)C1=NN=C(C(C2=C1C=C(C(=C2)OCC(=O)OCC)OC)CC)C AAVAGGUKVWHXPC-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QGHCURBJOMCZIF-UHFFFAOYSA-N n-phenyl-2,3-dihydro-1h-cyclopenta[b]quinolin-4-ium-9-amine;chloride Chemical compound Cl.C=12CCCC2=NC2=CC=CC=C2C=1NC1=CC=CC=C1 QGHCURBJOMCZIF-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU78GO1426A HU179018B (en) | 1978-10-19 | 1978-10-19 | Process for producing new 5h-2,3-benzodiazepine derivatives |
HUGO001426 | 1978-10-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI793209A7 FI793209A7 (fi) | 1980-04-20 |
FI66604B FI66604B (fi) | 1984-07-31 |
FI66604C true FI66604C (fi) | 1984-11-12 |
Family
ID=10996876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI793209A FI66604C (fi) | 1978-10-19 | 1979-10-16 | Foerfarande foer framstaellning av nya 5h-2,3-bensodiazepinderivat med inverkan pao det centrala nervsystemet |
Country Status (25)
Country | Link |
---|---|
US (1) | US4322346A (en, 2012) |
JP (1) | JPS5592377A (en, 2012) |
AT (1) | AT373589B (en, 2012) |
AU (1) | AU532079B2 (en, 2012) |
BE (1) | BE879404A (en, 2012) |
BG (1) | BG60270B2 (en, 2012) |
CA (1) | CA1125749A (en, 2012) |
CH (1) | CH643835A5 (en, 2012) |
CS (1) | CS236456B2 (en, 2012) |
DD (1) | DD146596A5 (en, 2012) |
DE (1) | DE2940483A1 (en, 2012) |
DK (1) | DK155327C (en, 2012) |
ES (1) | ES485163A1 (en, 2012) |
FI (1) | FI66604C (en, 2012) |
FR (1) | FR2439189A1 (en, 2012) |
GB (1) | GB2034706B (en, 2012) |
GR (1) | GR74034B (en, 2012) |
HU (1) | HU179018B (en, 2012) |
IT (1) | IT1220947B (en, 2012) |
NL (1) | NL190552C (en, 2012) |
NO (1) | NO152048C (en, 2012) |
PL (1) | PL124063B1 (en, 2012) |
SE (1) | SE439919B (en, 2012) |
SU (1) | SU1402258A3 (en, 2012) |
YU (1) | YU41887B (en, 2012) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU186760B (en) * | 1981-03-12 | 1985-09-30 | Gyogyszerkutato Intezet | Process for preparing 3,4-dihydro-5h-2,3-aenzodiazepine derivatives |
HU191702B (en) * | 1984-06-27 | 1987-03-30 | Gyogyszerkutato Intezet | New process for preparing 1-aryl-5 h-2,3-benzodiazepines |
HU191698B (en) * | 1984-07-27 | 1987-03-30 | Gyogyszerkutato Intezet | Process for producing new 1-aryl-5h-2beta-benzodiazepines |
HU195788B (en) * | 1986-05-21 | 1988-07-28 | Gyogyszerkutato Intezet | Process for producing 1-/hydroxy-stiryl/-5h-2,3-benzobiazepines and pharmaceutical compositions containing them |
JPH01311400A (ja) * | 1988-06-09 | 1989-12-15 | Kyocera Corp | 発光標識体の点灯方法 |
JPH0251568U (en, 2012) * | 1988-10-07 | 1990-04-11 | ||
JPH0324693U (en, 2012) * | 1989-07-18 | 1991-03-14 | ||
HU207055B (en) * | 1990-10-17 | 1993-03-01 | Gyogyszerkutato Intezet | Process for producing new 5h-2,3-benzodiazepine derivative and pharmaceutical compositions comprising same |
HU208429B (en) * | 1991-05-03 | 1993-10-28 | Gyogyszerkutato Intezet | Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity |
US5939412A (en) * | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
ZA924760B (en) * | 1991-06-28 | 1993-03-31 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
US6458784B1 (en) | 1994-06-29 | 2002-10-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
SK283859B6 (sk) * | 1995-02-09 | 2004-03-02 | Egis Gy�Gyszergy�R Rt. | 1-[2'-(Substituovaný)vinyl]-5H-2,3-benzodiazepínové deriváty, spôsob ich prípravy a medziprodukty na ich prípravu, liečivá ich obsahujúce a ich použitie |
HU224435B1 (hu) * | 1995-02-09 | 2005-10-28 | EGIS Gyógyszergyár Rt. | Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények |
DE69612413T2 (de) * | 1995-02-09 | 2001-09-27 | Egis Gyogyszergyar Rt., Budapest | 1-(Hetero)Arylvinyl-5H-2,3-benzodiazepinderivative verwendbar zur Behandlung von Erkrankungen des Zentralnervensystems, sowie Benzopyrylium Intermediate zu ihrer Herstellung |
US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
DE19604919A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
ES2111493B1 (es) * | 1996-02-08 | 1999-08-01 | Egyt Gyogyszervegyeszeti Gyar | Derivados de 1-(2- (vinilo substituido ) ) -5h-2,3-benzo-diazepina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y utilizaciones correspondientes. |
HU9600871D0 (en) * | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
ZA972746B (en) * | 1996-04-04 | 1998-10-09 | Egyt Gyogyszervegyeszeti Gyar | Novel 2,3-benzodiazepine derivatives |
HUP9701284A3 (en) * | 1997-07-24 | 2005-11-28 | Egyt Gyogyszervegyeszeti Gyar | Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system |
HU227128B1 (en) * | 1999-07-07 | 2010-07-28 | Egyt Gyogyszervegyeszeti Gyar | New 2,3-benzodiazepine derivatives |
FR2824065A1 (fr) * | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
US6649607B2 (en) * | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
AU2003263357B2 (en) * | 2002-09-13 | 2009-02-26 | Motac Neuroscience Limited | Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
AU2003267557B2 (en) * | 2002-09-17 | 2009-02-26 | Motac Neuroscience Limited | Treatment of dyskinesia |
CA2508542A1 (en) * | 2002-12-03 | 2004-06-17 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
US6864251B2 (en) * | 2002-12-03 | 2005-03-08 | Vela Pharmaceuticals, Inc. | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines |
US6638928B1 (en) * | 2002-12-03 | 2003-10-28 | Vela Pharmaceuticals, Inc. | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
EP1575521A4 (en) * | 2002-12-03 | 2008-04-30 | Vela Acquisition Corp | PHARMACEUTICAL COMPOSITION OF 1- (3-HYDROXY-4-METHOXYPHENYL) -4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND ITS USE |
US7022700B2 (en) * | 2002-12-03 | 2006-04-04 | Vela Pharmaceuticals, Inc. | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines |
US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
US20040224943A1 (en) * | 2003-02-19 | 2004-11-11 | Leventer Steven M. | Method of lowering body temperature with (R) - 2,3-benzodiazepines |
US20070021412A1 (en) * | 2003-05-16 | 2007-01-25 | Vela Pharmaceuticals, Inc. | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine |
CA2525273C (en) * | 2003-05-16 | 2012-04-17 | Vela Pharmaceuticals, Inc. | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine |
US20040254173A1 (en) * | 2003-06-13 | 2004-12-16 | Leventer Steven M. | Modulation of dopamine responses with substituted (S)-2,3-benzodiazepines |
HUP0302449A3 (en) * | 2003-08-04 | 2005-06-28 | Egis Gyogyszergyar Nyilvanosan | 8-chloro-2,3-benzodiazepine derivatives, pharmaceutical compositions containing them and process for producing them |
US7541355B2 (en) * | 2005-05-23 | 2009-06-02 | Vela Acquisition Corporation | Conversion process for 2,3-benzodiazepine enantiomers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1202579A (en) * | 1966-12-09 | 1970-08-19 | Egyt Gyogyszervegyeszeti Gyar | Pharmacologically active new isoquinoline derivative and process for preparing same |
DK118660B (da) * | 1966-12-09 | 1970-09-21 | Egyt Gyogyszervegyeszeti Gyar | Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid. |
USRE30014E (en) | 1966-12-09 | 1979-05-29 | Egyesult Gyogyazer-es Tapozergyar | 1-(3,4-Dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine |
ZA712798B (en) * | 1970-11-06 | 1972-02-23 | Egyt Gyogyszervegyeszeti Gyar | New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same |
-
1978
- 1978-10-19 HU HU78GO1426A patent/HU179018B/hu not_active IP Right Cessation
-
1979
- 1979-10-03 YU YU2410/79A patent/YU41887B/xx unknown
- 1979-10-04 AT AT0647279A patent/AT373589B/de not_active IP Right Cessation
- 1979-10-05 DE DE19792940483 patent/DE2940483A1/de active Granted
- 1979-10-12 SE SE7908481A patent/SE439919B/sv not_active IP Right Cessation
- 1979-10-15 BE BE1/9569A patent/BE879404A/fr not_active IP Right Cessation
- 1979-10-16 AU AU51817/79A patent/AU532079B2/en not_active Ceased
- 1979-10-16 FI FI793209A patent/FI66604C/fi not_active IP Right Cessation
- 1979-10-16 CH CH929279A patent/CH643835A5/de not_active IP Right Cessation
- 1979-10-16 FR FR7925698A patent/FR2439189A1/fr active Granted
- 1979-10-16 CS CS797020A patent/CS236456B2/cs unknown
- 1979-10-17 DD DD79216290A patent/DD146596A5/de not_active IP Right Cessation
- 1979-10-17 GR GR60290A patent/GR74034B/el unknown
- 1979-10-18 JP JP13471879A patent/JPS5592377A/ja active Granted
- 1979-10-18 CA CA337,955A patent/CA1125749A/en not_active Expired
- 1979-10-18 GB GB7936185A patent/GB2034706B/en not_active Expired
- 1979-10-18 SU SU792832177A patent/SU1402258A3/ru active
- 1979-10-18 BG BG45206A patent/BG60270B2/bg unknown
- 1979-10-18 ES ES485163A patent/ES485163A1/es not_active Expired
- 1979-10-18 IT IT7926579A patent/IT1220947B/it active
- 1979-10-18 DK DK440179A patent/DK155327C/da not_active IP Right Cessation
- 1979-10-18 NO NO793349A patent/NO152048C/no unknown
- 1979-10-18 NL NLAANVRAGE7907692,A patent/NL190552C/xx not_active IP Right Cessation
- 1979-10-18 PL PL1979219034A patent/PL124063B1/pl unknown
-
1980
- 1980-09-26 US US06/191,811 patent/US4322346A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI66604C (fi) | Foerfarande foer framstaellning av nya 5h-2,3-bensodiazepinderivat med inverkan pao det centrala nervsystemet | |
CA1150246A (en) | .beta.-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME | |
IL100449A (en) | N-acylated-1-(4-aminophenyl)-7,8-methylenedioxy-5H-2,3-benzodiazepine derivatives their preparation and pharmaceutical compositions containing them | |
Pages et al. | 1-Amino-2-(4-imidazolyl) cyclopropanecarboxylic Acid1a | |
RU2058982C1 (ru) | 1-(3-хлорфенил)-4-оксиметил-7,8-диметокси-5н-2,3-бензо-диазепин или его терапевтически приемлемая соль присоединения кислоты | |
US3520901A (en) | Tetrahydroindazoles | |
SU1169538A3 (ru) | Способ получени трициклических соединений | |
HRP920897A2 (hr) | Spojevi indenoindola i postupak za njihovo dobivanje | |
US4057560A (en) | 1,2,2A,3,4,5 Hexahydrobenz[c,d]indol-1-yl-2-guanidines | |
Aknin et al. | A new synthetic approach to functionalize pyrimido [4, 5-b] quinoline-2, 4 (1 H, 3 H)-diones via a three-component one-pot reaction | |
HU185329B (en) | Process for preparing quinolone derivatives and pharmaceutical compositions containing such compounds | |
HU191702B (en) | New process for preparing 1-aryl-5 h-2,3-benzodiazepines | |
Mekheimer et al. | 1, 8-Naphthyridines II: Synthesis of novel polyfunctionally substituted 1, 8-naphthyridinones and their degradation to 6 aminopyridones | |
FI89357B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara benso- och cyklohepta/1,2-c;3,4-c'/dipyrazolderivat | |
JPS6137249B2 (en, 2012) | ||
US3503990A (en) | 6-aryl-4,5,6,7-tetrahydro-4-oxoindole derivatives | |
PT97570A (pt) | Processo para a preparacao de derivados de benzotienopiridina | |
JPS6228146B2 (en, 2012) | ||
SU1616515A3 (ru) | Способ получени производных пиррола или их оптических изомеров либо фармацевтически приемлемых солей | |
PT86154B (pt) | Processo para a preparacao de novos pirrolobenzimidazoles e de composicoes farmaceuticas que os contem | |
US4016165A (en) | Triazino benzodiazepines | |
DK156391B (da) | Analogifremgangsmaade til fremstilling af 3-aminopyrrolderivater | |
JPH09508637A (ja) | 5ht2bレセプタ拮抗薬縮合インドール | |
HRP960564A2 (en) | Quinoxaline compounds, pharmaceutical preparations containing them and a process for the preparation thereof | |
AT395155B (de) | Verfahren zur herstellung von neuen imidazo(1,5-a)(1,4)diazepinverbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Patent lapsed | ||
MM | Patent lapsed |
Owner name: E GY T GYOGYSZERVEGYOERZETI GYOER |